The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection
- PMID: 17875002
- DOI: 10.1111/j.1365-2893.2006.00838.x
The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection
Abstract
Hepatitis C virus (HCV) is a leading cause of chronic liver disease that can progress to cirrhosis and/or hepatocellular carcinoma. Intrahepatic inflammation and liver cell injury are defining features of chronic HCV infection. Chemokines, chemotactic cytokines that attract leucocytes to inflammatory sites, may be important in the development of intrahepatic inflammation. As T-helper (Th)1 inflammatory cells, characterized by interferon (IFN)-gamma and interleukin (IL)-2 secretion, predominate in the liver during chronic HCV infection, chemokines that attract these cells might be particularly important in disease progression. In this review, we focus on the role of Th1 chemokines, which are all members of the CXC or CC subfamilies. Among the CXC chemokines, the non-ELR group comprised of IFN-gamma-inducible protein 10 (IP-10), monokine induced by IFN-gamma (Mig) and IFN-inducible T-cell-alpha chemoattractant (I-TAC), attract Th1 cells through the interaction with their receptor, CXCR3. Among the CC subfamily, Th1-associated chemokines include regulated upon activation, normal T-cell expressed and secreted (RANTES) and macrophage inflammatory proteins (MIP)1alpha and beta. These chemokines attract cells through an interaction with their receptor, CCR5. While peripheral blood and intrahepatic levels of all of these chemokines are elevated in chronic hepatitis C patients, only select chemokines have been found to be correlated with hepatic inflammation. Among the six chemokines, IP-10 has uniquely been shown to have prognostic utility as a marker of treatment outcome. In the future, chemokines might be used to monitor the natural course and progression of HCV-associated liver disease, to identify patients with a high likelihood of achieving a therapeutic response, and they may even have potential as therapeutic targets.
Similar articles
-
Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver.J Immunol. 1999 Dec 1;163(11):6236-43. J Immunol. 1999. PMID: 10570316
-
I-TAC/CXCL11 is a natural antagonist for CCR5.J Leukoc Biol. 2004 Sep;76(3):701-8. doi: 10.1189/jlb.1103570. Epub 2004 Jun 3. J Leukoc Biol. 2004. PMID: 15178708
-
Chemokine expression during the development and resolution of a pulmonary leukocyte response to influenza A virus infection in mice.J Leukoc Biol. 2004 Oct;76(4):886-95. doi: 10.1189/jlb.1203644. Epub 2004 Jul 7. J Leukoc Biol. 2004. PMID: 15240757
-
Hepatocellular carcinoma and CXCR3 chemokines: a narrative review.Clin Ter. 2017 Jan-Feb;168(1):e37-e41. doi: 10.7417/CT.2017.1980. Clin Ter. 2017. PMID: 28240761 Review.
-
Chemokines in hepatitis C virus infection: pathogenesis, prognosis and therapeutics.Cytokine. 2007 Jul;39(1):50-62. doi: 10.1016/j.cyto.2007.05.013. Epub 2007 Jul 16. Cytokine. 2007. PMID: 17629707 Review.
Cited by
-
Serum IP-10 Levels Correlate with the Severity of Liver Histopathology in Patients Infected with Genotype-1 HCV.Gut Liver. 2011 Dec;5(4):506-12. doi: 10.5009/gnl.2011.5.4.506. Epub 2011 Nov 21. Gut Liver. 2011. PMID: 22195251 Free PMC article.
-
A lymphotoxin-driven pathway to hepatocellular carcinoma.Cancer Cell. 2009 Oct 6;16(4):295-308. doi: 10.1016/j.ccr.2009.08.021. Cancer Cell. 2009. PMID: 19800575 Free PMC article.
-
Molecular mechanisms of liver fibrosis in HIV/HCV coinfection.Int J Mol Sci. 2014 May 26;15(6):9184-208. doi: 10.3390/ijms15069184. Int J Mol Sci. 2014. PMID: 24865485 Free PMC article. Review.
-
Intrahepatic expression of genes related to metabotropic receptors in chronic hepatitis.World J Gastroenterol. 2012 Aug 21;18(31):4156-61. doi: 10.3748/wjg.v18.i31.4156. World J Gastroenterol. 2012. PMID: 22919248 Free PMC article.
-
Injecting drug use and hepatitis C virus infection independently increase biomarkers of inflammatory disease risk which are incompletely restored by curative direct-acting antiviral therapy.Front Immunol. 2024 Feb 14;15:1352440. doi: 10.3389/fimmu.2024.1352440. eCollection 2024. Front Immunol. 2024. PMID: 38420130 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials